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An adipose extracellular matrix derived biomaterial, Acellular Adipose Tissue, 
can be used as an off-the-shelf alternative to autologous fat transfer for the treatment of 
soft tissue deformities and defects. This tissue engineering solution overcomes many 
challenges associated with autologous fat transfer and other common methods of soft 
tissue reconstruction. Subcutaneous Acellular Adipose Tissue implants display 
significant volume retention with minimal inflammatory response in both pre-clinical and 
clinical studies. The material triggers cell migration which supports development of new 
adipose and has also demonstrated the potential to modulate the immune response to 
create a more pro-regenerative microenvironment in the presence of trauma. These results 
indicate that Acellular Adipose Tissue could be a promising new therapeutic tool to treat 
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Soft tissue defects are relatively common and can occur due to trauma, congenital 
disease, or surgical inventions. As tissue loss is often permanent, these defects can impact 
not only cosmesis but also normal physiological function, including lack of support for 
distal extremities and contracture leading to restricted range of motion [1]. The gold 
standard for soft tissue reconstruction is autologous adipose transfer (otherwise known as 
fat grafting), a procedure first developed by Gustav Neuber over a century ago  [2, 3]. 
However, although these procedures are still commonly used today and many 
advancements have been introduced, autologous fat transfer techniques have many 
limitations. Adipose grafts behave unpredictably and outcomes can often vary 
significantly from patient to patient.  The grafted tissue can be resorbed anywhere from 
20%-90%, decreasing the total volume of the graft and often requiring multiple surgical 
procedures to achieve the desired correction. Like any surgical procedure, autologous fat 
grafting carries inherent safety risks. The unpredictability of these procedures can result 
in costly surgeries and co-morbidities related to tissue harvest. Harvest procedures often 
lead to scarring at the donor site and are limited by the volume of autologous tissue 
available in each patient [4]. Transplanted adipocytes are often damaged or subjected to 
hypoxic conditions that result in the release of intracellular lipids, a potent pro-
inflammatory signal. These signals combined with a lack of vascularization within the 
graft can lead to tissue necrosis and calcifications which impact the quality and durability 
of the reconstructed tissue [5]. 
Decellularized extracellular matrix (ECM) products are a type of biomaterial that 
have recently gained popularity in the field of regenerative medicine, although they have 
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been studied and used in various clinical applications since as early as 1995 [6]. Unlike 
synthetic biomaterials such as polymers, ECM materials are tissue-derived and are 
created using physical, enzymatic, and chemical approaches that remove the living cells 
from almost any type of animal or human tissue [7]. These decellularization processes 
disrupt cellular membranes and denature key intracellular components such as DNA, but 
leave behind the non-cellular component which is present in all tissues and organs. This 
non-cellular component is mainly structural in nature and is known as the extracellular 
matrix (ECM). Although all ECMs are composed of water, proteins, and polysaccharides, 
the physical characteristics and exact composition of any specific ECM depends on its 
tissue of origin. ECMs have many physiological roles, including providing a physical 
scaffold and initiating cues required for tissue homeostasis and differentiation. ECM also 
directs function by binding to growth factors and interacting with receptors on the cell 
surface [8]. 
ECM scaffolds are commonly used in tissue engineering to promote the healing or 
regrowth of damaged tissue. Initially, they provide a physical substrate upon which the 
cells can be seeded and localized to a specific area. They also provide key biochemical 
and physical cues for adhesion, migration, proliferation, and differentiation which help 
cells to form fully functional tissues or organs. Implanted ECM scaffolds will eventually 
be remodeled and be replaced with the seeded cells’ own secreted matrices.  
ECM has many beneficial uses and new applications that are currently being 
explored in regenerative medicine. In the past 15 years, many ECM materials have been 
brought to market and been successfully used clinically. Alloderm®, an ECM product, 
has been used for dentistry, burn therapy, plastic surgery, and hernia repair for over 13 
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years. Many decellularized bone allografts have also been successfully marketed and 
used clinically for bone reconstruction. In one case, a complicated scaffold made of 
porcine small intestinal sub-mucosa ECM was used to treat a quadriceps defect in a 19-
year-old marine three years post-injury, resulting in remarkable improvement after only 4 
months [9]. The complex protein and polysaccharide composition and unique physical 
structures of an ECM cannot be mimicked using any synthetic biomaterial currently 
available, and thus these biomimetic scaffolds effectively modulate signal transduction 
and both directly and indirectly regulate cellular function  similar to natural ECM [10]. 
The remarkable successes of ECM products already on the market and the potential 
benefits of ECM materials due to their biomimetic properties indicate that the possible 
clinical applications of these materials are vast. 
Adipose tissue is where the body stores excess energy and regulates metabolic 
homeostasis by synthesizing and secreting various compounds. It is made up mostly of 
adipocytes, but also consists of blood cells, endothelial cells, adipose precursor cells, 
pericytes, and other cells in the stromal vascular fraction. Adipocytes can increase 
primarily in size but also in number in order to store excess energy produced from food 
[11]. Adipose is also a robust source of mesenchymal stem cells, called adipose-derived 
stem cells (ASCs), which have the potential to differentiate into multiple lineages [12].  
As per their role as energy suppliers for the body, adipose cell signaling can have 
a significant impact on overall health. It has been noted clinically that transplanting 
autologous fat can have a positive impact on surrounding tissues. This includes 
improvements in both scarring and aging skin. Perhaps more strikingly, autologous fat 
transfers have also improved radiation damage, damaged vocal cords, and chronic 
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ulceration. These improvements may be related to undifferentiated cells, such as ASCs, 
in the adipose tissue [13]. These clinical observations indicate an important connection 
between adipose tissue and wound healing. 
Adipose tissue is a practical raw material source for producing ECM biomaterials 
for several reasons.  To start, adipose is relatively abundant and easy to harvest, whether 
from a deceased tissue donor or in a minimally invasive procedure for autologous use. An 
adult human can have a body fat composition of anywhere from less than 10% (a lean 
individual) to more than 50% (an obese individual) [14]. Additionally, adipose contains 
secreted factors that are beneficial for angiogenesis, anti-inflammation, and anti-
apoptosis [15, 16].  Importantly, adipose tissue can also play a role in immune 
modulation. The metabolic processes carried out by adipose tissue, including adipocyte 
expansion and thermogenesis, can activate both the adaptive and innate immune system 
[17]. All of these qualities of adipose tissue make it an ideal candidate for a 
decellularized ECM biomaterial for use in wound healing and reconstruction 
applications. 
When addressing the challenges of wound healing and reconstruction, it is 
important to understand the role of the immune system. Immune cells are important in 
every step of the wound healing process, from debridement to new tissue and scar 
formation. Neutrophils arrive at the wound site about 24 hours after injury. Their main 
role is to debride the wound and decrease the likelihood of infection. Approximately 48-
96 hours after injury, macrophages migrate in and promptly become the predominant cell 
population. They contribute to and conclude wound debridement and secrete cytokines 
and growth factors that play a key role in cell recruitment and regulation during tissue 
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repair, including both angiogenesis and new matrix deposition. On approximately the 
fifth day following injury, T lymphocytes migrate into the wound and regulate the 
proliferation phase of tissue repair [18].   
As the immune system’s contribution to and regulation of tissue development and 
regeneration is becoming better understood [19], tissue engineers are beginning to realize 
that it is important to approach regeneration with the immune system in mind. Recent 
studies have identified the role of T helper 2 cells in the biomaterial scaffold directed 
tissue repair [20] and examined the role of macrophages in the remodeling process after 
implantation of a surgical mesh [21]. It is also important to note that macrophage 
phenotype plays a key role in wound healing. Macrophages exist on a spectrum ranging 
from “M1 macrophages” which are typically described as pro-inflammatory to “M2 
macrophages” which are considered regulatory or homeostatic [21]. Macrophage 
heterogeneity [22] and its implications for wound healing [23] can have a huge impact on 
the design of biomaterials to elicit pro-regenerative responses. 
The work in this thesis describes the immunological characterization and Phase I 
clinical testing of an adipose extracellular matrix product, called Acellular Adipose 
Tissue (AAT). This product was developed at Johns Hopkins University in the laboratory 
of Dr. Jennifer Elisseeff and is intended to fill the clinical need for an "off-the-shelf" soft 
tissue repair technology for volume augmentation and soft tissue reconstruction. AAT 
provides a structure that mimics normal soft tissue and a matrix to promote cell migration 
and new fat tissue growth. Extensive preclinical studies have characterized the physical 
properties and evaluated compatibility and efficacy in vivo [24, 25], including an 
evaluation of new adipose tissue development in athymic mice and biocompatibility in 
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immune competent rodents. The in vivo behavior of the AAT was evaluated in multiple 
animal models including mouse, rat, and swine in comparison to the current clinical gold 
standard of autologous fat grafting.  Overall, these results highlight the biocompatibility 
of the AAT implants and their ability to provide soft tissue volume replacement. They 
also show an advantage autologous fat grafting which may cause calcification due to an 
inflammatory response to released intracellular lipids [3, 26].   
Studies done by Dr. Elisseeff and the Biomaterials and Tissue Engineering Lab at 
Johns Hopkins investigating the immunological profile of various ECM-derived scaffolds 
[20] suggest that the constituents of an ECM scaffold can alter the immune 
microenvironment of the tissue. These studies establish a critical role for the local 
immunological microenvironment in wound healing and suggest that the immune-
modulating properties of ECM-based biomaterials such as AAT may be used in a 
targeted manner to facilitate wound healing.  Human clinical studies and animal research 
aimed to investigate the immunocomposition of AAT and determine the resulting impact 






Human cadaveric adipose tissue was obtained from Donor Network West and shipped to 
Johns Hopkins at -20˚C. Porcine adipose tissue was obtained from Wagner Meats and 
delivered to Johns Hopkins at 4˚C and stored at -20°C. Tissue was thawed at room 
temperature immediately prior to use (porcine tissue was warmed to 37˚C in a water bath 
prior to processing). The tissue was dissected into 1 cm3 pieces and mechanically pressed 
until all lipids were removed. The tissue was then incubated in 3% peracetic acid for 3 
hours at room temperature stirred at 300 RPM. The tissue was rinsed with Dulbecco’s 
phosphate buffered saline (DPBS) + HEPES buffer six times and then pH tested. Once 
the pH became neutral (7 or greater), tissue was incubated in Triton X-
100/ethylenediaminetetraacetic acid (EDTA) overnight at room temperature with 
continuous stirring at 300 RPM. The following day, the treated tissue was rinsed in DPBS 
until no bubbles appeared upon agitation. Water was then pressed out of the tissue and 
the moisture content was analyzed. The tissue was then knife milled and DPBS was 
added until the moisture content was 91% (± 1%). The final ECM product is stored in 
capped 5 mL syringes at 4˚C for up to 1 year. All processing is done in a biosafety 
cabinet to ensure sterility. The clinical lot was manufactured at the Johns Hopkins Cell 
Therapy Laboratory's GMP manufacturing facility in accordance with good 
manufacturing practices (GMP). 
 
In preclinical studies, several lots of human adipose-derived AAT (hAAT) and one lot of 
porcine adipose-derived AAT (pAAT) were assessed. A single lot of GMP-manufactured 
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hAAT was used in Phase I clinical testing (TS-0680). Biochemical characterization 
studies were performed on the GMP-manufactured hAAT clinical lot (TS-0268) and a 
second non-GMP hAAT batch that was manufactured sterilely in a biosafety cabinet 
according to Good Laboratory Practices (TS-0267). A pAAT batch was also 
manufactured sterilely in the lab according to the same protocol (PA1). All in vivo animal 
studies were performed using the hAAT lab batch (TS-0267) and the pAAT lab batch 
(PA1). Unlike the clinical lot, the two non-GMP batches used in animal testing were not 
terminally sterilized by gamma irradiation, though sterility was carefully maintained.  
 
VML Surgeries 
Animals were anesthetized using 4% isoflurane and maintained during the surgery using 
2.5% isoflurane.  Hair was removed at the surgical site, and the area was sterilized with 
70% ethanol. An incision was created from just above the knee to the hip. A 3 mm x 3 
mm defect was created in the quadricep muscle using surgical scissors. The defect was 
filled with 0.05 cc of either ECM material or sterile DPBS (Gibco) as a control. The 
incision was closed using 3-5 sterilized wound clips (Roboz Surgical). Immediately 
following surgery, animals received carprofen (Rimadyl, Zoetis) subcutaneously at 5 
mg/kg for pain. Animals were then monitored until waking. At the desired study end 
points (1, 3, or 6 weeks), animals were sacrificed and both quadriceps and all inguinal 
(local) lymph nodes, and axillary / brachial (distal) lymph nodes were removed. All 
samples designated for gene expression analysis were immediately transferred into 
RNAlater (ThermoFisher), stored at 4˚C for 24 hours, and then moved to -80˚C if 
ribonucleic acid (RNA) isolations were not to be performed immediately. Quadriceps for 
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flow cytometry analysis were processed immediately after removal. All animal 
procedures were performed in accordance with protocols approved by Johns Hopkins 
Institutional Care and Use Committee (IACUC). 
 
Subcutaneous Injections 
Animals were anesthetized using 4% isoflurane and maintained during the surgery using 
2.5% isoflurane.  The area was sterilized using 70% ethanol. Animals received two 0.20 
cc injections of ECM into the subcutaneous space at superior and inferior positions on the 
dorsal side of the animal. Animals were then monitored until waking. At desired study 
end points (1 or 3 weeks), animals were sacrificed and samples were collected (implants 
and inguinal, axillary, and brachial lymph nodes). For flow cytometry and gene 
expression analysis, any skin was cut away from the implant. For histology, skin and 
implant were harvested together. 
 
Flow cytometry 
Harvested animal or human tissue was finely diced in 1X DPBS on ice. Diced tissue was 
then digested in an enzyme solution consisting of 1.67 Wunsch U/ml Liberase TL 
(Sigma-Aldrich) and 0.2 mg/ml DNAse I (Roche) in serum-free RPMI 1640. Digested 
tissue was then filtered sequentially through 100 μm and 70 µm filters. Cells were then 
pelleted at 4°C at 300xg for 10 minutes. In some cases, the cell pellets were enriched for 
hematopoietic cells using Lympholyte (Cedarlane) reagent. Remaining cells were then 
washed in DPBS (300xg for 5 minutes), then resuspended in a viability dye and stained 
for 30 minutes on ice, then washed, then stained 45 minutes on ice with the flow 
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cytometry antibody mixtures (see panel summary in Tables 1 and 2 below). Stained cells 
were then washed and fixed using Cytofix (BD Biosciences), then washed and stored in 
DPBS for up to 24 hours prior to data acquisition. Data was obtained using an LSR II 
flow cytometer (BD Biosciences) and analysis was conducted with FlowJo software. 
 
Table 1. Mouse flow cytometry panel for subcutaneous injection studies 
Conjugate Antigen Phenotype Staining Dilution 
AF488 CD3 T cells 1:250 
BV421 CD19 B cells 1:400 
PE-Cy7 F4/80 Macrophages 1:250 
APC-Cy7 CD11c Dendritic cells 1:200 
AF700 CD86 M1 macrophages 1:200 
APC CD206 M2 macrophages 1:400 
 
Table 2. Mouse flow cytometry panel for volumetric muscle loss studies 
Conjugate Antigen Phenotype Staining Dilution 
PerCP/Cy5.5 CD11c Dendritic cells 1:100 
PE-Cy5 CD3 T cells 1:200 
PE-594 (CF) Siglec-F* Eosinophils 1:200 
PE CD206 M2 macrophages 1:250 
Pacific Blue Ly6g Neutrophils 1:400 
PE-Cy7 F4/80 Macrophage 1:250 
APC CD86 M1 macrophages 1:400 
BV605 CD45 Hematopoetic cells 1:150 
AF488 MHCII I-A/I-E Antigen presentation 1:200 
AF700 CD11b Myeloid cell 1:400 
BV510 Ly-6C Monocytes 1:300 
 
Unless otherwise noted, all antibodies were obtained from Biolegend. Antibodies marked 
with (*) were obtained from BD Biosciences.  
 
RT-qPCR 
Tissue was thawed and removed from RNAlater, rinsed in PBS and then homogenized in 
TRIzol (Life Technologies) using fine scissors and RNase-free pestles. RNA was isolated 
by chloroform extraction, then the aqueous layer containing RNA was transferred to a 
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fresh tube containing an equal volume of 70% ethanol. The mixture was then applied to 
RNeasy Mini columns (Qiagen) and purified according to the manufacturer's instructions. 
RNA was eluted in RNase-free water and quantified using a Qubit 2.0 fluorometer 
(Invitrogen). RNA was treated to remove residual DNA using a cocktail containing 
DNase I, 10x DNase buffer and RNaseOUT inhibitor according to reagent protocols (Life 
Technologies). Complementary deoxyribonucleic acid (cDNA) synthesis was conducted 
using Superscript Reverse Transcriptase (RT) III enzyme as per manufacturer's 
instructions (Life Technologies). Real time quantitative polymerase chain reaction 
(qPCR) was conducted on Applied Biosystems Real Time PCR machines using SYBR 
Green as a reporter. Primer sequences are included in Table 3.  
 
Table 3. Real time quantitative PCR Primer Sequences 
Gene Forward Primer (5' → 3') Reverse Primer (5' → 3') 
Arg1 ACAAGACAGGGCTCCTTTCAG TAAAGCCACTGCCGTGTTCA 
Retnlα CAGCTGATGGTCCCAGTGAAT AGTGGAGGGATAGTTAGCTGG 
Tnfα ATGGCCTCCCTCTCATCAGT TGGTTTGCTACGACGTGGG 
Il-4 GGTCACAGGAGAAGGGACGC AGCACCTTGGAAGCCCTACA 
Il-10 CAGGACTTTAAGGGTTACTTGGGT GCCTGGGGCATCACTTCTAC 
Il-1β TGCCACCTTTTGACAGTGATG AAGCTGGATGCTCTCATCAGG 
iNos CTTGGTGAAGGGACTGAGCTG GTTCTCCGTTCTCTTGCAGTTG 
Ifnγ CGGCACAGTCATTGAAAGCC TGTCACCATCCTTTTGCCAGT 
Gata3 CTCCTTGCTACTCAGGTGATCG AGGGAGAGAGGAATCCGAGT 
B2m CACTGAATTCACCCCCACTGA TCTCGATCCCAGTAGACGGT 
 
Histology 
Samples were fixed in 10% formalin, serially dehydrated in graded ethanol solutions, and 
embedded in paraffin. Microtome sectioning was performed to obtain sections of 5 μm 
thickness. Slides were stained using a standard Hematoxylin and Eosin (H&E) staining 





Animals were trained on the treadmill apparatus 48 hours prior to testing. During the 
training, the treadmill was set to 5 m/min and increased by 1 m/min every minute for 5 
minutes. During testing, mice were run to exhaustion starting at a speed of 5 m/min and 
increased by 1 m/min every minute. The mice were considered exhausted when they 
remained on the pulsed shock grid for 30 continuous seconds. All treadmill testing was 
done at least 48 hours prior to the study end points where tissue samples were collected.  
 
Clinical Trial 
Eight healthy volunteers were injected with AAT in redundant tissue previously 
scheduled for surgical removal in an elective surgical procedure (i.e. panniculectomy, 
abdominoplasty). Each patient received a total of 2 mL of AAT in one (2 mL injection) 
or two injection sites (1 mL injection). Participants had follow-up visits at 1, 2, and 4 
weeks post-injection (if implant has not yet been excised) and 2 and 6 weeks post-
excision. Pain and itching were assessed at all follow-up visits. Implants were excised 
during an elective surgical procedure after 1, 2, 4, 6 or 18 weeks in situ and delivered to 
the lab (tissue was transported on 4°C gel packs if travel time exceeded 20 minutes). 
Tissue samples were photographed, dissected, weighed, and transferred to the appropriate 
storage or processing reagent for downstream analysis. Panel-reactive antibody testing at 
4 and 12 weeks post injection (independent of the excision time-point) indicated if the 





Cell Migration Assay 
AAT-triggered cell migration was measured using a transwell assay relative to several 
control solutions: 10% fetal bovine serum (FBS) in serum free media for a positive 
control, 1% PBS in serum free media for a buffer control, and serum free media alone for 
a negative control. Human adipose-derived stem cells (ASCs) were thawed and grown in 
basic growth media supplemented with 1 ng/mL basic fibroblastic growth factor (bFGF) 
and passaged and split once at approximately 80% confluency, with media changes every 
2-3 days. Upon reaching 80% confluency a second time, cells were serum starved for 24 
hours prior to performing assay. After starvation, cells were trypsinized and a single cell 
suspension was created at 300,000 cells/mL in serum free media. Sample was prepared 
by adding AAT to serum free media at a 1% (v/v) concentration and vortexing. In some 
assays, samples incubated at room temperature for 15 minutes and centrifuged to remove 
large chunks of AAT that might stick to the transwell membrane. Sample, 10% FBS, 1% 
buffer and serum free media (600 µl) were added in triplicate wells of a 24 well plate, a 
transwell insert was placed on top, and the plate was allowed to acclimate in an 
incubator. After acclimation, 100 μL of the cell suspension was added into the upper 
chamber of each transwell (300,000 cells per well) and incubated at 37˚C for 6 hours. All 
cells remaining on the upper side of the membrane were removed using a cotton swab 
and any excess AAT was removed from the lower membrane by rinsing in DPBS. 
Transwells were fixed in methanol for 15 minutes at room temperature, stained with 
DAPI, and then imaged within 72 hours. Cell nuclei were counted in a 50x field of view. 





The total lipid content of biomaterials was quantified using a triglyceride colorimetric 
assay. Adipose samples and AAT were minced into 1 mm or smaller pieces to disrupt 
physical barriers and release lipids. Organic extraction was conducted by the Schwartz 
method and enzymatic reactions were carried out using Infinity TG Reagent according to 
the manufacturer's protocol. Absorbance was measured at 540 nm and concentration of 
the samples was determined using a glycerol standard curve (samples prepared in water). 
 
Collagen Content 
Since hydroxyproline is largely restricted to collagen, the measurement of 
hydroxyproline levels can be used as an indicator of collagen content. In this assay, 
hydroxyproline concentration is determined by a reaction of oxidized hydroxyproline 
with 4-(Dimethylamino)benzaldehyde (DMAB), which results in a colorimetric (560 nm) 
product, proportional to the hydroxyproline present. Sample preparation consisted of 
lyophilization and hydrochloric acid hydrolysis of 10 mg of sample (dry weight) at 120˚C 
for 3 hours. The hydrolyzed samples were diluted 100x and added in triplicate to a 96 
well plate in multiple dilutions, along with samples for a hydroxyproline standard curve. 
A spiked control was also used to detect any interfering endogenous compounds. All 
wells in the plate were evaporated to dryness. The colorimetric reaction was carried out 
using reagents provided in the Hydroxyproline Assay Kit (Sigma) according to the 
manufacturer's instructions. Absorbance was measured at 560 nm and the standard curve 





A batch of AAT was manufactured without EDTA or Triton-X100 to serve as a negative 
control in the development of these assays. To determine the amount of residual EDTA in 
the clinical AAT lot, a semi-quantitative method was developed using Quantofix EDTA 
test strips. The test method was validated using standard solutions of known EDTA 
concentration and confirming the expected result obtained from the strip. A known 
concentration of EDTA was spiked into the control batch of AAT post-production to 
ensure that none of the components of the AAT would interfere with the validity of the 
test strips. To perform the test, samples were centrifuged and supernatant was collected 
and applied to the test strips. Strips were read according to the manufacturer's 
instructions.  
 
Residual triton X-100 levels in AAT were quantified by reverse phase high-performance 
liquid chromatography (HPLC). The control batch manufactured without Triton-X100 
served as a negative control in these experiments. Triton-X100 standards were prepared 
in water and run along with the AAT samples. AAT and spiked control samples were 
prepared for HPLC by repeated centrifugation at >12,000 rpm to remove insoluble 
proteins and collect aqueous supernatant. Soluble proteins were then precipitated using 
methanol-chloroform extraction. Both the aqueous and organic layers were collected and 
combined. The protein pellet was washed with chloroform and the supernatant was also 
combined with the sample (discarding the protein pellet). Samples were concentrated by 
freeze-drying in a lyophilizer until completely dry, then resuspended in a consistent 
volume of pure water for HPLC. An isocratic reverse phase separation was performed 
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using an HC-C18(2) column and two mobile phases: HPLC-grade water and 100% 
acetonitrile. The peak corresponding to Triton-X100 was measured and quantified 
relative to standards.  
  
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism software. In grouped analyses 
with a single variable, significance was determined by one-way analysis of variance 
(ANOVA) using the Holm-Sidak correction for multiple comparisons where applicable 
(α = 0.05). Significance in grouped analyses with two variables was calculated using two-
way ANOVA with Tukey post-hoc testing (α = 0.05). P values less than 0.05 were 
considered statistically significant (* < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001). 
Plotted values represent the arithmetic or geometric mean (RT-qPCR data only) of the 







 Building on previous studies done in the Elisseeff lab which characterized the 
physical properties of AAT, we initially sought to study the biochemical characteristics 
of AAT. Biochemical assays performed included an in vitro cell migration assay, residual 
chemicals testing, a lipid content assay, and a collagen content assay. There were two 
main purposes for collecting this data: to get a better understanding of the biochemical 
composition and properties of the material, and to start building a database with the goal 
of understanding the batch–to–batch differences in AAT. This information will help 
define the expected variability from both tissue donors and from any changes in the 
manufacturing process, and will be critical for scaling up the manufacturing protocols for 
later stage clinical trials and eventual commercialization. The biochemical 
characterizations also allowed us to study how the terminal sterilization process of 
gamma irradiation might change the properties of the final product. 
 The in vitro cell migration assays were conducted on both irradiated and non-
irradiated samples from the human clinical batch (TS-02568) (Figure 1). The results of 
these assays showed that both the irradiated and the non-irradiated samples of human 
AAT promote cell migration of ASCs across a transwell membrane. In a pilot 
experiment, images taken of the transwell membrane showed that the non-irradiated AAT 
was more likely to stick to the membrane, potentially indicating a difference in 
mechanical properties. A second assay was performed with the samples centrifuged to 
remove large chunks that might stick to membrane, thus ensuring migration would only 
be triggered by interaction with soluble factors. In this second assay, the non-irradiated 

































smoother and more homogenous. Cell infiltration occurs from the surrounding tissues 
into the implant, indicating that the material promotes cell migration and corroborating 
the results of the in vivo cell migration assay. It is also interesting to note the brown fat 
pad adjacent to the implant in the superior position (visible in the pAAT 3-week top 
section) which could potentially impact the cellular response to the material. 
 The immune cell profile of the subcutaneous implants after 1 or 3 weeks in vivo 
were assessed using flow cytometry (Figure 5). Overall, the flow analysis showed that 
human and porcine AAT had similar immune cell profiles at each time point. A greater 
percentage of the cells migrating into the implant were CD206+ macrophages (M2 
polarized) than CD86+ (M1 polarized) macrophages, suggesting that the biomaterial 
 
Figure 5. Subcutaneous flow cytometry results at 1 and 3 weeks. Implants were 
pooled for each animal to ensure adequate cell number for analysis. Statistical 
significance calculated using two-way ANOVA with TUKEY post-hoc testing for 
everything except F4/80hi macrophage activation for which a one-way ANOVA with 
TUKEY post-hoc testing was used. * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001. 
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skews macrophage polarization towards an M2 phenotype. When considering this result, 
it is important to understand that macrophage polarization is spectrum rather than a 
binary change, so macrophages could potentially be somewhere between an M1 and an 
M2 phenotype. It was also noted that the level of macrophage activation (F4/80hi relative 
to F4/80lo) was higher at 1 week than at 3 weeks. The percentage of CD3+ T cells in the 
implant is significantly higher at 3 weeks than at 1 week, indicating that the T cell 
response begins prior to 1 week and increases to a peak at some later time point. 
 Gene expression analysis performed on the SQ implants at 3 weeks post-injection 
showed that iNos, an M1 gene, and Arg1, an M2 gene, were both significantly increased 
in almost all of the implants (Figure 6). The increase in iNos gene expression in the 
pAAT far implant was not considered statistically significant. This information is 
interesting given the higher percentage of CD206+ M2 macrophages than CD86+ M1 
macrophages in the implant observed in the flow cytometry data. Other genes including 
Il-4 were elevated in the implant relative to normal muscle, but these results were not 
statistically significant.  
 A mouse volumetric muscle wound (VML) model was used to study the response 
to both pAAT and hAAT in a wound environment. In this experiment, a critical sized 
defect was created in the mouse quadriceps muscle and was filled with a biomaterial or 
saline as a control. To explore whether there was an effect related to xenogenic AAT in 
the mouse wound model, these experiments also included mouse-derived AAT produced 
from C57BL/6 mice as a syngeneic ECM control. Response to the biomaterials was 




Figure 6. Subcutaneous RT-PCR results at 3 weeks. Implants in the superior position 
and inferior positions were analyzed separately relative to gene expression in uninjured 
quadriceps muscle. Significance calculated using two-way ANOVA with TUKEY post-
hoc testing. Asterisks with no line indicate significance compared to uninjured. * < 0.05, 
** < 0.01, *** < 0.001, **** < 0.0001. 
 
 Flow cytometry results of the 1 week VML study included a mouse AAT 
(mAAT) group to analyze the immune response to a genetically-matched ECM material 
(Figure 7). There were significantly more immune cells in quadriceps treated with hAAT 
and pAAT than those treated with mAAT or saline. Overall, the immune cell profile of 
wounds treated with mAAT more closely resembled those treated with saline than the 




Figure 7. Volumetric muscle loss flow cytometry results at 1 week. Groups labeled as 
“uninj.” are uninjured quads from age-matched animals. Statistical significance 
calculated using a one-way ANOVA with Tukey post-HOC testing. Significance without 
lines indicate significance compared to uninjured. * < 0.05, ** < 0.01, *** < 0.001, **** 
< 0.0001. 
 
in both pAAT and hAAT. The xenogeneic AATs also recruited a much stronger 
eosinophil response (Siglec-F+MHCII-). Interestingly, wounds treated with mAAT were 
the only group with a statistically significant increase in the proportion of T cells 
compared to uninjured quads. However, this there was no significant difference in the  
absolute number of T cells at the wound site between the different ECM treatments (data 
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not shown). The data also indicates that pAAT and hAAT promote greater skewing of 
polarized macrophages to an M2-like phenotype than mAAT, though overall mAAT is 
still somewhat M2-polarizing. Saline treatment promotes a more M1-like phenotype than 
any ECM treatment, as determined by the relative proportions of CD206+CD86- and 
CD86+CD206- macrophages. 
RT-qPCR analysis of the wounded muscle 1 week after treatment showed that 
wounds treated with mouse syngeneic AAT were not significantly different than wounds 
treated with saline or uninjured muscle in any of the genes tested (Figure 8). Most of 
these M2 genes - including Il-4, Arg1, and Retnlα - were significantly increased in pAAT 
and hAAT treated wounds compared to saline treated wounds and uninjured muscle. 
Increases were also observed in M1 genes relative to saline treatment; though these 
increases were generally similar between different ECMs. Most importantly, expression 
of Il-4 increased more than 100-fold in pAAT and hAAT relative to control groups, 
whereas mAAT also increased but was not significantly different than saline. Taken 
together, these results are consistent with flow cytometry analysis of macrophage 
polarization and indicate a difference in the profile of immune cells migrating to wounds 
treated with syngeneic ECM than those treated with xenogeneic ECMs. 
A human clinical trial studied the safety of AAT when implanted subcutaneously 
in human participants. The primary outcome measures of this study were histopathology, 
safety, and patient and physician satisfaction. On an exploratory basis, the immune cell 




Figure 8. Volumetric muscle loss RT-PCR results at 1 week. Statistical significance is 
calculated relative to saline controls. * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001. 
 
Histological analysis of the clinical trial implants showed minimal negative 
inflammatory response with cell migration into the implant (Figure 10), demonstrating 
the potential for new tissue formation. The implants also show good volume retention at 
up to 18 weeks post-injection, the latest time-point studied. The implants do not show any 
indication of capsule or cyst formation or tissue necrosis. All of these histological results 
indicate demonstrate the biocompatibility of AAT when implanted into humans and that 
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Preclinical studies showed promising results for the safe and effective use of AAT 
for soft tissue reconstruction in humans. In both VML and subcutaneous studies in mice, 
AAT demonstrated good tissue integration with cell migration into the implant. No 
significant inflammatory response was noted in these experiments. Results obtained from 
the subcutaneous implants indicate that macrophages begin migrating in from the 
surrounding tissue within 1 week. By three weeks, however, the macrophages are no 
longer as dominant and adaptive cells such as T cells have begun to appear. This mimics 
the immune response to a wound during which macrophages enter the wound first 
followed by lymphocytes [18]. RT-qPCR analysis showed an increase in gene expression 
for both iNos, the inducible form of nitric oxide synthase, and Arg1, Arginase 1. The iNos 
gene generates nitric oxide and is an important enzyme in the macrophage inflammatory 
response [27]. Arg1 is an enzyme that metabolizes arginine and is highly expressed on 
M2 macrophages. Resident adipose tissue-associated macrophages typically have M2-
like polarization and express Arg1 and are important for balancing inflammation in fat 
tissue and maintaining metabolism. Interestingly, Arg1 and iNos compete to metabolize 
arginine when they are co-expressed [28]. The co-expression of iNos and Arg1 likely 
indicates that the macrophages present within the AAT at 3 weeks are neither purely M1 
nor M2, though they may be skewed towards M2 at a population level. 
 Flow cytometry analysis of the AAT-treated quadriceps muscles at 1 week after 
critical injury showed significant infiltration of immune cells into the wound site. Overall 
the flow data suggest similarity between the xenogeneic AATs, including an increased 
percentage of recruited immune cells (CD45+), eosinophils (CD45+ CD11b+ SiglecF+ 
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MHCII-), and M2 macrophages (CD206+CD86-) relative to saline and uninjured 
controls. Although the differences were not significant, syngeneic mouse AAT was also 
somewhat more M2-polarizing than saline alone, and recruited greater percentages of 
immune cells.  However, the macrophages present in mouse AAT tended to be more M1-
polarized (CD86+) than in the other AATs. Gene expression analysis also showed that 
significantly more interleukin 4 (Il-4) was present in wounds treated with both pig and 
human AAT than those treated with saline or mouse AAT.  This indicates that in some 
contexts, AAT promotes the migration of immune cells which trigger the release of this 
key pro-regenerative cytokine.  This increased expression of Il-4 is not correlated with an 
increase in the proportion or absolute number of T cells in the wound, but may be due to 
the increased activity of myeloid cells orchestrating the upregulation of Il-4. Missing 
from these analyses are quantifications of different T cells subsets, particularly TH2 
helper T cells, which are essential for creating a pro-regenerative microenvironment.  
The combined results of our syngeneic versus xenogeneic AAT studies indicate 
that pro-regenerative immune responses to ECM are likely not driven by non-specific 
damage-associated molecular patterns (DAMPs) inherent to all ECMs [29]. It is possible 
that a response related to foreign antigens in both the pig and human AAT is significantly 
driving the observed increases in Il-4 expression, eosinophils, or M2 macrophage 
polarization. However, there are likely factors other than species contributing to the 
differences observed between AAT treatments. Biochemical characterizations of the 
mouse AAT may reveal a key difference that helps to explain the loss of the pro-
regenerative phenotype. More rapid resorption of the mouse AAT compared to the 
xenogeneic materials may also be preventing the immune system from mounting a full 
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M2/Th2 response. Additional studies will be needed to confirm the mechanism or 
mechanisms driving these phenotypes. Future work will investigate an allogeneic ECM 
material in the wound environment in order to better understand the implications of these 
results for the translation of AAT to clinical applications. 
In Phase I clinical trial studies, AAT proved safe, biocompatible, and well-
tolerated by all outcomes measured. No serious adverse events were reported, and all 
anticipated adverse events were mild and localized to the injection site. Both physicians 
and participants reported overall satisfaction with the comfort/ease of use and appearance 
of the injected area. Importantly, implant volume was retained until the latest measured 
time point of 18 weeks, and the material integrated into the surrounding tissue rather than 
becoming isolated by fibrosis.  Histological analysis of the implants also showed 
significant cell migration into the implant from surrounding tissue which generally 
increased as time went on. Although immune cells were observed within the implant, the 
lack of a systemic immune reaction suggests that any immune-modulation is occurring 
locally. All of this data indicates that AAT is safe for use in humans and has the potential 
to support cell infiltration and new tissue formation. Future analyses will be conducted to 
identify specific types of immune cells present in the AAT. It will be critical to determine 
whether these cells are pro-inflammatory immune cells, pro-regenerative immune cells, 
or stem cells to fully understand the cellular response to the material.   
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CONCLUSION AND FUTURE WORK 
This work describes the development of an adipose-tissue derived ECM material 
for soft tissue reconstruction, including many of the material characterizations and 
preclinical studies that lead to the first in human study. These preclinical results and 
others were critical in obtaining FDA approval for initial clinical testing. Consequently, 
the safety results obtained from this first clinical study will be leveraged to advance AAT 
to Phase II clinical testing to confirm safety and determine efficacy in patients.  Our most 
recent animal studies have sought to identify the mechanisms of ECM-mediated 
immunomodulation and will be critical to help define clinical indications for AAT and 
inform future research.  
In these preclinical studies, AAT demonstrated volume retention, significant 
tissue integration, and minimal inflammation. Subcutaneous implants attracted large 
proportions of macrophages around 1 week, followed later by the clearing of the 
macrophages and increased migration of T cells. In a mouse wound environment, pig and 
human AAT elicited a strong M2-macrophage response while syngeneic mouse AAT 
elicited a more neutrally-polarized macrophage response that was similar to saline treated 
wounds. However, CD3+ T cell response was not significantly impacted by ECM tissue 
source, which may suggest a combination of factors (both species-specific and non-
species specific properties of ECMs) is responsible for the immune response to these 
materials. The ability of AAT to modulate immune response and induce a favorable pro-
regenerative environment could potentially be harnessed to improve wound healing and 
reduce scarring after injury. This data indicates that AAT could be a good substitute for 
autologous fat transfer in the treatment of soft tissue defects. 
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 Future studies will determine the immune response to allogeneic ECM in a wound 
model and determine mechanisms contributing to the ECM-associated immune 
microenvironment. Biochemical characterizations will continue for each new 
manufactured lot to form an understanding of batch-to-batch variability and help 
determine which properties of the material are correlated with successful clinical 
outcomes. These factors and others will be considered for design and validation of a 
scaled-up manufacturing process for future clinical trials involving significantly more 
participants. Together, this work will enable Phase II clinical testing, which will be 
conducted to test the safety and efficacy of AAT in filling small soft tissue defects in 
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